{{Drugbox
| IUPAC_name = ''N''-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-3-(4-fluorophenyl)-1''H''-pyrazole-5-carboxamide 
| image = AB-CHFUPYCA_chemical_structure.png

<!--Clinical data-->
| tradename =  
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = Schedule II
| legal_UK = <!-- GSL         / P       / POM / CD / Class A, B, C -->
| legal_US = <!-- OTC                   / Rx-only  / Schedule I, II, III, IV, V -->
| legal_status = 
| routes_of_administration =

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number =none<!-- last chacked 20/nov/15 -->
| ATC_prefix =  
| ATC_suffix =  
|  ChemSpiderID = 
|  smiles = O=C(NC(C(N)=O)C(C)C)C1=CC(C2=CC=C(F)C=C2)=NN1CC3CCCCC3
|  StdInChI = 1S/C22H29FN4O2/c1-14(2)20(21(24)28)25-22(29)19-12-18(16-8-10-17(23)11-9-16)26-27(19)13-15-6-4-3-5-7-15/h8-12,14-15,20H,3-7,13H2,1-2H3,(H2,24,28)(H,25,29)
|  StdInChIKey = NDYOOVJIZQTGHY-UHFFFAOYSA-N

<!--Chemical data-->
| C=22 | H=29 | N=4 | O=2 | F=1
| molecular_weight = 400.50 g/mol
}}

'''AB-CHFUPYCA''' (also '''AB-CHMFUPPYCA''')<ref name=McLaughlin>{{cite journal | url=http://onlinelibrary.wiley.com/doi/10.1002/dta.1864/abstract | title=The synthesis and characterization of the 'research chemical' ''N''-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-3-(4-fluorophenyl)-1''H''-pyrazole-5-carboxamide (3,5-AB-CHMFUPPYCA) and differentiation from its 5,3-regioisomer |author1=Gavin McLaughlin |author2=Noreen Morris |author3=Pierce V. Kavanagh |author4=John D. Power |author5=Brendan Twamley |author6=John O'Brien |author7=Brian Talbot |author8=Geraldine Dowling |author9=Simon D. Brandt | journal=Drug Testing and Analysis | volume=8 | issue=9 | pages=920 |date=September 2015  | doi=10.1002/dta.1864| pmid=26360802 }}</ref> is a compound that was first identified as a component of [[synthetic cannabis]] products in Japan in 2015.<ref>{{cite journal | url=https://link.springer.com/article/10.1007%2Fs11419-015-0283-8 | title=A new pyrazole-carboxamide type synthetic cannabinoid AB-CHFUPYCA [''N''-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-3-(4-fluorophenyl)-1''H''-pyrazole-5-carboxamide] identified in illegal products | last2=Asakawa | first2=K. | last3=Kikura-Hanajiri | first3=R. | last4=Tsutsumi | first4=T. | last5=Hakamatsuka | first5=T. | journal=Forensic Toxicology | volume=33 | issue=2 | pages=367–373 | doi=10.1007/s11419-015-0283-8 | first1=N. | last1=Uchiyama | date=August 2015}}</ref><ref>{{cite journal | url=http://onlinelibrary.wiley.com/doi/10.1002/dta.1950/abstract | title=In vitro metabolism of the synthetic cannabinoid 3,5-AB-CHMFUPPYCA and its 5,3-regioisomer and investigation of their thermal stability |author1=Florian Franz |author2=Verena Angerer |author3=Simon D. Brandt |author4=Gavin McLaughlin |author5=Pierce V. Kavanagh |author6=Bjoern Moosmann |author7=Volker Auwärter | journal=Drug Testing and Analysis | volume=9 | issue=2 | pages=311 | date=2016 | doi=10.1002/dta.1950| pmid=26888282 }}</ref> The name "'''AB-CHFUPYCA'''" is an acronym of its systematic name ''N''-(1-'''A'''mino-3-methyl-1-oxo'''B'''utan-2-yl)-1-('''C'''yclo'''H'''exylmethyl)-3-(4-'''F'''l'''U'''orophenyl)-1''H''-'''PY'''razole-5-'''C'''arbox'''A'''mide. There are two known regioisomers of AB-CHFUPYCA:  3,5-AB-CHMFUPPYCA (pictured) and 5,3-AB-CHMFUPPYCA.<ref>{{cite web | url=https://www.caymanchem.com/product/18296 | title=5-fluoro-3,5-AB-PFUPPYCA | publisher=Cayman Chemical Company | accessdate=25 May 2017}}</ref> The article[1] refers to both 3,5-AB-CHMFUPPYCA and 5,3-AB-CHMFUPPYCA as AB-CHMFUPPYCA isomers, so AB-CHMFUPPYCA and AB-CHFUPYCA are not names for a unique chemical structure.

Although AB-CHFUPYCA contains structural elements common to the synthetic cannabinoid designer drugs [[AB-PINACA]] and [[AB-FUBINACA]], it can also be considered an analog of the traditional [[pyrazole]] cannabinoid receptor 1 antagonist [[rimonabant]]. Its pharmacological properties have not been studied.

==See also==
{{div col|colwidth=30em}}
* [[5F-AB-FUPPYCA]]
* [[5F-AB-PINACA]]
* [[5F-ADB]]
* [[5F-AMB]]
* [[5F-APINACA]]
* [[AB-CHMFUPPYCA]]
* [[AB-FUBINACA]]
* [[AB-PINACA]]
* [[ADB-CHMINACA]]
* [[ADB-FUBINACA]]
* [[ADB-PINACA]]
* [[ADBICA]]
* [[APICA]]
* [[APINACA]]
* [[MDMB-CHMICA]]
* [[Rimonabant]]
{{Div col end}}

==References==
<references/>

{{Cannabinoids}}

[[Category:Cannabinoids]]
[[Category:Designer drugs]]
[[Category:Fluoroarenes]]
[[Category:Pyrazoles]]
[[Category:Pyrazolecarboxamides]]


{{cannabinoid-stub}}